Dan H Barouch

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard, Boston, MA 02114, USA Electronic address
    Cell 155:531-9. 2013
  2. pmc Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Infect Dis 207:248-56. 2013
  3. pmc Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:8694-8. 2012
  4. pmc Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection
    Ritu R Bradley
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:625-9. 2012
  5. pmc Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 482:89-93. 2012
  6. pmc Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:8729-35. 2003
  7. ncbi request reprint HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 364:10-1. 2004
  8. pmc Challenges in the development of an HIV-1 vaccine
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 455:613-9. 2008
  9. ncbi request reprint Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Vaccine 22:3092-7. 2004
  10. doi request reprint Bovine adenovirus vectored vaccine for avian influenza
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Ther 16:807-8. 2008

Detail Information

Publications85

  1. pmc Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA Ragon Institute of MGH, Massachusetts Institute of Technology and Harvard, Boston, MA 02114, USA Electronic address
    Cell 155:531-9. 2013
    ..These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest a potential strategy for the development of a global HIV-1 vaccine. PAPERCLIP: ..
  2. pmc Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)
    Dan H Barouch
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA
    J Infect Dis 207:248-56. 2013
    ..ENVA.01), are reported concurrently with this article. Here, we characterize in greater detail the humoral and cellular immune responses elicited by Ad26.ENVA.01 in humans...
  3. pmc Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:8694-8. 2012
    ..Overall, the data suggest that vaccines and microbicides are complementary techniques that may protect better when used together than separately...
  4. pmc Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection
    Ritu R Bradley
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:625-9. 2012
    ..A novel chimeric Ad5 vector in which both the hexon HVRs and the fiber knob were exchanged nearly completely evaded Ad5-specific NAbs both in vitro and in vivo...
  5. pmc Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 482:89-93. 2012
    ..These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys...
  6. pmc Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:8729-35. 2003
    ..These data demonstrate that plasmid cytokines can markedly improve the immunogenicity of DNA prime-viral vector boost vaccine strategies and can partially compensate for antivector immunity...
  7. ncbi request reprint HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 364:10-1. 2004
  8. pmc Challenges in the development of an HIV-1 vaccine
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 455:613-9. 2008
    ..Here I review key challenges and future prospects in the quest to develop a prophylactic HIV-1 vaccine...
  9. ncbi request reprint Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Vaccine 22:3092-7. 2004
    ....
  10. doi request reprint Bovine adenovirus vectored vaccine for avian influenza
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Ther 16:807-8. 2008
  11. ncbi request reprint Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nat Immunol 6:247-52. 2005
    ....
  12. ncbi request reprint Adenovirus vector-based vaccines for human immunodeficiency virus type 1
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Hum Gene Ther 16:149-56. 2005
    ..In this review, we describe progress in the development of rAd vector-based vaccines with a focus on human immunodeficiency virus type 1...
  13. ncbi request reprint Rational design of gene-based vaccines
    Dan H Barouch
    Research East Room 113, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Pathol 208:283-9. 2006
    ..In this review, current strategies to develop and optimize gene-based vaccines are described, with an emphasis on novel approaches to improve plasmid DNA vaccines and recombinant adenovirus vector-based vaccines...
  14. ncbi request reprint Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 172:6290-7. 2004
    ..Moreover, these studies suggest that using Ad vectors derived from immunologically distinct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-existing anti-Ad immunity...
  15. pmc Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Virol 83:9584-90. 2009
    ..Inclusion of Env resulted in improved control of peak and set point SIV RNA levels following challenge. In contrast, DNA vaccine priming did not further improve the protective efficacy of rAd5HVR48 vectors in this system...
  16. pmc International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Vaccine 29:5203-9. 2011
    ..These data inform the clinical development of alternative serotype rAd vaccine vectors in the developing world...
  17. pmc HIV-1 vaccine development after STEP
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    Annu Rev Med 61:153-67. 2010
    ..We review the current state of the HIV-1 vaccine field and outline strategies that are being explored to overcome these roadblocks...
  18. pmc Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Nat Med 16:319-23. 2010
    ..Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such as HIV-1...
  19. pmc Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:7367-75. 2003
    ..These data suggest that CTL exert selective pressure on viral replication and that viral escape from CTL may be a limitation of CTL-based AIDS vaccine strategies...
  20. pmc Novel adenovirus vector-based vaccines for HIV-1
    Dan H Barouch
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Curr Opin HIV AIDS 5:386-90. 2010
    ..These vectors are being explored as potential vaccine candidates for a variety of pathogens. This review summarizes current efforts to develop rAd vector-based vaccines for HIV-1...
  21. pmc Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
    Sampa Santra
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P O Box 15732, Boston, MA 02215, USA
    J Virol 79:6516-22. 2005
    ..Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection...
  22. pmc Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines
    Shawn M Sumida
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 114:1334-42. 2004
    ..Synergistic recruitment and expansion of DCs in vivo may prove a practical strategy for overcoming this limitation and potentiating immune responses to vaccines as well as other immunotherapeutic strategies...
  23. pmc Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
    Peter Abbink
    Research East Room 213, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 81:4654-63. 2007
    ..These studies substantially expand the portfolio of rare serotype rAd vectors that may prove useful as vaccine vectors for the developing world...
  24. pmc Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 82:4844-52. 2008
    ..Moreover, qualitative differences in cellular immune responses may prove critical in determining the overall potency of heterologous rAd prime-boost regimens...
  25. pmc Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 181:4188-98. 2008
    ..Thus, i.m. vaccination can overcome immune compartmentalization and generate robust mucosal CD8(+) T lymphocyte memory. These data demonstrate that the systemic and mucosal immune systems are highly coordinated following vaccination...
  26. pmc Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys
    Lauren E Grandpre
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
    Vaccine 27:1549-56. 2009
    ..Together, these studies suggest that a multi-dose vaccine regimen utilizing up to four inoculations of MVA generates robust and durable antibody-mediated immunity comparable to that elicited by replication-competent VV...
  27. pmc Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection
    Sampa Santra
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 76:6376-81. 2002
    ..These data indicate that prior vaccination can increase the breadth of the CTL response that evolves after an AIDS virus infection...
  28. ncbi request reprint Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes
    Yue Sun
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 174:4753-60. 2005
    ..Persisting clinical protection in vaccinated and challenged monkeys is thus correlated with a preserved capacity of the peripheral blood central memory CD4+ T cells to express this important immunomodulatory cytokine...
  29. ncbi request reprint Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
    Dan H Barouch
    Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Research East Room 113, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 415:335-9. 2002
    ..These data indicate that viral escape from CTL recognition may be a major limitation of the CTL-based AIDS vaccines that are likely to be administered to large human populations over the next several years...
  30. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  31. pmc Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors
    Shawn M Sumida
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 78:2666-73. 2004
    ..Novel adenovirus vectors that are currently being developed to circumvent the problem of preexisting anti-Ad5 immunity should therefore be designed to evade both humoral and cellular Ad5-specific immune responses...
  32. pmc Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination
    Paul F McKay
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:4695-702. 2003
    ....
  33. pmc Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys
    Anjali Nanda
    Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    J Virol 79:14161-8. 2005
    ..Moreover, these studies demonstrate that capsid chimeric rAd vectors can be constructed to combine beneficial immunologic and serologic properties of different Ad serotypes...
  34. ncbi request reprint Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys
    Paul F McKay
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Immunol 168:332-7. 2002
    ..Moreover, an AIDS vaccine that confers protection against clinical disease evolution in this experimental model also preserves the functional capacity of these CTL to produce both IL-2 and TNF-alpha...
  35. pmc Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys
    Jinyan Liu
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Virol 84:10406-12. 2010
    ..These findings have implications for the design and interpretation of HIV-1 vaccine efficacy studies...
  36. ncbi request reprint Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein
    Shawn M Sumida
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 174:7179-85. 2005
    ..These studies suggest a potential strategy for engineering novel Ad5 vectors to evade dominant Ad5-specific NAbs...
  37. pmc TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector
    Elizabeth G Rhee
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Virol 84:10413-9. 2010
    ..Moreover, these findings suggest the potential utility of TLR4 ligands as adjuvants for rAd vector-based vaccines...
  38. ncbi request reprint Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
    Diane M Roberts
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 441:239-43. 2006
    ..Such chimaeric viral vectors may have important practical implications for vaccination and gene therapy...
  39. pmc Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity
    Anna R Thorner
    Research East Room 213, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 80:12009-16. 2006
    ....
  40. pmc Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5
    Katherine Masek-Hammerman
    New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts 017721, USA
    J Virol 84:9810-6. 2010
    ....
  41. pmc A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 79:8828-34. 2005
    ..This strategy could therefore be explored as a potential method to enhance DNA vaccine immunogenicity in humans...
  42. pmc Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses
    Sampa Santra
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:11088-93. 2004
    ..This study, therefore, indicates that the steady-state memory, rather than the peak effector vaccine-elicited T lymphocyte responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine...
  43. pmc Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
    Kara L O'Brien
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Nat Med 15:873-5. 2009
    ..These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study...
  44. pmc Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies
    Jinyan Liu
    Research East Room 213, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 80:11991-7. 2006
    ....
  45. pmc Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys
    Ramu A Subbramanian
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Research East RE 113, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 77:10113-8. 2003
    ..These studies suggest that multiepitope plasmid DNA vaccine-based prime-boost regimens can efficiently prime for CTL responses of increased breadth and magnitude, although they do not overcome predicted hierarchies of immunodominance...
  46. ncbi request reprint Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF
    Dan H Barouch
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 168:562-8. 2002
    ..These results demonstrate that bicistronic DNA vaccines containing GM-CSF elicit remarkably potent CD4(+) T cell responses and suggest that optimal Th cell priming requires the precise temporal and spatial codelivery of Ag and GM-CSF...
  47. pmc Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes
    David R Kaufman
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, E CLS 1047, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 84:5986-96. 2010
    ..m. or i.n. rAd immunization. Our findings indicate that the anatomic microenvironment of antigen expression critically impacts the phenotype and trafficking of antigen-specific CD8(+) T lymphocytes...
  48. ncbi request reprint Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses
    Paul F McKay
    Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston 02215, USA
    Eur J Immunol 34:1011-20. 2004
    ..Moreover, these studies show that different subsets of professional APC can selectively modulate DNA vaccine-elicited T lymphocyte responses...
  49. pmc A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
    Sampa Santra
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:10489-94. 2008
    ..These findings suggest that immunization with centralized genes is a promising vaccine strategy for developing a global vaccine for HIV-1 as well as vaccines for other genetically diverse viruses...
  50. pmc Use of molecular beacons for rapid, real-time, quantitative monitoring of cytotoxic T-lymphocyte epitope mutations in simian immunodeficiency virus
    Fred W Peyerl
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Clin Microbiol 43:4773-9. 2005
    ..This real-time PCR technique for evaluating CTL epitope mutations may prove to be a useful tool for monitoring the genetic drift of human immunodeficiency virus and SIV in infected individuals...
  51. pmc Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope
    Fred W Peyerl
    Harvard Medical School, Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, Research East Room 113, 330 Brookline Ave, Boston, MA 02215, USA
    J Virol 78:13901-10. 2004
    ....
  52. pmc Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys
    Hualin Li
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:10862-5. 2012
    ..These data contribute to our understanding of Ad26 as a candidate vaccine vector...
  53. pmc Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys
    Hualin Li
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Virol 85:11007-15. 2011
    ..Vaccine-elicited T(EM) responses at mucosal surfaces may prove critical for affording protection against invading pathogens at the mucosal portals of entry...
  54. pmc Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope
    Fred W Peyerl
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 77:12572-8. 2003
    ..Together, these data suggest that a compensatory mutation is selected for in SHIV strain 89.6P to facilitate the escape of that virus from CTL recognition of the dominant p11C, C-M epitope...
  55. pmc Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice
    David R Kaufman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Virol 82:6829-37. 2008
    ..These studies also suggest that rAd vectors warrant further assessment as candidate subunit smallpox vaccines...
  56. pmc Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys
    Kathryn E Stephenson
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:11434-40. 2012
    ....
  57. pmc Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 82:5643-9. 2008
    ..Combining in vivo EP with plasmid chemokine adjuvants that similarly recruited APCs to the injection site, however, did not result in synergy...
  58. ncbi request reprint Prospects for vaccine protection against HIV-1 infection and AIDS
    Norman L Letvin
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Annu Rev Immunol 20:73-99. 2002
    ..We then describe vaccine strategies that have been explored and discuss the evidence suggesting that cellular immune responses elicited by novel vaccine modalities may attenuate clinical disease caused by HIV-1...
  59. pmc Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions
    Ritu R Bradley
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, and Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA
    J Virol 86:1267-72. 2012
    ..These data have important implications for the development of novel vectors for both vaccines and gene therapy...
  60. pmc Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa
    Anna R Thorner
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Research East, Room 213, 330 Brookline Avenue, Boston, MA 02215, USA
    J Clin Microbiol 44:3781-3. 2006
    ..We observed a clear age dependence of Ad5-specific neutralizing antibody titers. These data will help to guide the development of Ad vector-based vaccines for human immunodeficiency virus type 1 and other pathogens...
  61. pmc Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
    Eric S Rosenberg
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10555. 2010
    ..clinicaltrials.gov NCT00125099)..
  62. pmc Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys
    Jeffrey E Teigler
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:9590-8. 2012
    ..These differences in innate triggering result in markedly different immunologic milieus for the subsequent generation of adaptive immune responses by these vaccine vectors...
  63. pmc HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
    James M Kovacs
    Division of Molecular Medicine, Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 109:12111-6. 2012
    ..These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development...
  64. pmc Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors
    Pablo Penaloza-MacMaster
    Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 87:1373-84. 2013
    ..These data suggest that vaccination with alternative-serotype Ad vectors offers substantial immunological advantages over Ad5 vectors, in addition to circumventing high baseline Ad5-specific neutralizing antibody titers...
  65. pmc Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys
    Jinyan Liu
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Virol 86:7829-35. 2012
    ..These results suggest the potential of an accelerated heterologous rAd prime-boost regimen as a candidate HIV-1 vaccine for newborns...
  66. pmc Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys
    Kathryn E Stephenson
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 86:9583-9. 2012
    ..These data suggest the importance of including Gag in an HIV-1 vaccine in which virologic control is desired...
  67. pmc Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys
    David R Kaufman
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
    Vaccine 30:506-9. 2012
    ..These data suggest that antigen-independent factors contribute to the immunodominance patterns of vaccine-elicited cellular immune responses...
  68. ncbi request reprint Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes
    Fred W Peyerl
    Division of Viral Pathogenesis, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Viral Immunol 17:144-51. 2004
    ....
  69. pmc Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys
    Andrew B Wilks
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    J Immunol 185:7097-106. 2010
    ....
  70. pmc Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs
    Joseph P Nkolola
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, E CLS 1047, 330 Brookline Avenue, Boston, MA 02215, USA
    J Virol 84:3270-9. 2010
    ....
  71. pmc Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors
    Elizabeth G Rhee
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    J Virol 85:315-23. 2011
    ..Stimulation of multiple innate immune mechanisms may prove a generalizable property of potent vaccines, and this strategy could be harnessed in the development of next-generation vaccine vectors and adjuvants...
  72. ncbi request reprint The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Immunol Rev 202:266-74. 2004
    ..Here, we review recent advances in our understanding of cytokine biology, T-lymphocyte differentiation, and potential applications of plasmid cytokines in the rational design of improved vaccines...
  73. pmc Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity
    David R Kaufman
    Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 187:1877-83. 2011
    ....
  74. pmc Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys
    So yon Lim
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Genet 6:e1000997. 2010
    ..34 or 0.36, respectively. These findings call into question the premise that CCL3L CNV is important in HIV/SIV pathogenesis...
  75. ncbi request reprint Viral evolution and challenges in the development of HIV vaccines
    Dan H Barouch
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Research East Room 113, Boston, MA 02215, USA
    Vaccine 20:A66-8. 2002
    ..These data suggest that viral escape from CTL may prove to be a significant limitation of the current generation of CTL-based AIDS vaccines...
  76. pmc Disseminated trichosporonosis caused by Trichosporon loubieri
    Francisco M Marty
    Division of Infectious Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Microbiol 41:5317-20. 2003
    ..Trichosporonosis is an emerging invasive fungal infection in immunosuppressed patients; a case of disseminated infection caused by Trichosporon loubieri presented confirms its role as a human pathogen...
  77. ncbi request reprint BK virus-associated hemorrhagic cystitis in a Human Immunodeficiency Virus-infected patient
    Dan H Barouch
    Division of Infectious Diseases, Massachusetts General Hospital, and Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA, USA
    Clin Infect Dis 35:326-9. 2002
    ....
  78. pmc Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity
    Angelique A C Lemckert
    Crucell Holland B V, Leiden, The Netherlands
    J Virol 79:9694-701. 2005
    ..Nevertheless, these data suggest the potential utility of heterologous rAd prime-boost vaccine regimens using vectors derived from rare human Ad serotypes...
  79. ncbi request reprint DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate
    Mary Premenko-Lanier
    California National Primate Research Center and Department of Pathology, School of Medicine, University of California Davis, County Road 98, Davis, CA 95616 8542, USA
    Virology 307:67-75. 2003
    ..Further, the addition of a molecular IL-2 adjuvant augments this DNA vaccine...
  80. ncbi request reprint HIV-1 vaccine candidate ineffective
    Dan H Barouch
    AIDS Clin Care 19:93. 2007
  81. ncbi request reprint Challenges in the search for an HIV vaccine
    Angelique A C Lemckert
    Crucell Holland BV, 2301 CA Leiden, The Netherlands
    Eur J Epidemiol 19:513-6. 2004
    ..An immunogen that elicits broadly reactive neutralizing antibodies, however, has yet to be developed...
  82. ncbi request reprint Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity
    Angelique A C Lemckert
    Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands
    J Gen Virol 87:2891-9. 2006
    ..SIVGag vaccine. These data demonstrate the potential of a replication deficient human group D adenoviral vector for vaccination purposes...
  83. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  84. doi request reprint Adenovirus serotype 5 hexon mediates liver gene transfer
    Simon N Waddington
    Department of Haematology, Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, London NW3 2PF, UK
    Cell 132:397-409. 2008
    ..Liver infection by the FX-Ad5 complex is mediated through a heparin-binding exosite in the FX serine protease domain. This study reveals an unanticipated function for hexon in mediating liver gene transfer in vivo...
  85. ncbi request reprint HIV vaccine trial canceled
    Dan H Barouch
    AIDS Clin Care 20:69. 2008

Research Grants16

  1. Impact of HIV Envelope Conformation on Immunogenicity
    Bing Chen; Fiscal Year: 2010
    ..In this proposal, we will assess the impact of HIV-1 envelope conformation on the profile of elicited neutralizing antibody responses. ..
  2. Impact of HIV Envelope Conformation on Immunogenicity
    DAN BAROUCH; Fiscal Year: 2009
    ..In this proposal, we will assess the impact of HIV-1 envelope conformation on the profile of elicited neutralizing antibody responses. ..
  3. Novel Adenovirus Vaccine Vectors for HIV/SIV
    Dan H Barouch; Fiscal Year: 2010
    ..abstract_text> ..
  4. Novel Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2009
    ..abstract_text> ..
  5. Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV
    DAN BAROUCH; Fiscal Year: 2007
    ..The long-term objectives of these studies are to develop novel vaccine regimens that recruit APCs to the site of inoculation in animal models and to consider advancing the most promising strategies into clinical trials. ..
  6. Novel Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2007
    ....
  7. Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Raphael Dolin, Dean for Clinical Programs, Harvard Medical School, will guide Dr. Barouch's development as an independent investigator. In addition, a committee of distinguished scientists will oversee his progress toward independence. ..
  8. Chimeric Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Within the two-year time frame of this award, sufficient data will be generated with candidate chimeric rAd vaccines to justify further vaccine/challenge studies in rhesus monkeys. ..